Immunocore Holdings PLC (fra:6YG) Share Price

Company Profile

Business description
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Contact
92 Park Drive
Milton Park
AbingdonOxfordshireOX14 4RY
GBR
T: +44 1235438600
E: [email protected]
https://www.immunocore.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
493

Recommended

We think Microsoft stock is moderately undervalued.

Dan Romanoff, CPA | 30 October 2025

Q3 earnings reflected sequential improvement driven by record auto deliveries and energy storage deployments.

Seth Goldstein, CFA | 30 October 2025

Well priced Aussie shares that offer a tax rebate.

Shani Jayamanne | 29 October 2025

Index	Last price	Change	% Change
All Ordinaries	9,178.00	28.70	-0.31%
CAC 40	8,113.47	43.82	-0.54%
DAX 40	23,944.08	174.81	-0.72%
Dow JONES (US)	47,595.62	73.50	0.15%
FTSE 100	9,717.80	42.26	-0.43%
HKSE	25,906.65	376.04	-1.43%
NASDAQ	23,793.46	212.31	0.90%
Nikkei 225	52,411.34	1,085.73	2.12%
NZX 50 Index	13,548.32	89.03	0.66%
S&P 500	6,854.53	32.19	0.47%
S&P/ASX 200	8,881.90	31.30	-0.35%
SSE Composite Index	3,954.79	32.11	-0.81%